Artículo
Purinergic signaling pathway in severe COVID-19
Fecha de publicación:
06/2023
Editorial:
Elsevier
Revista:
Current Opinion In Pharmacology
ISSN:
1471-4892
Idioma:
Inglés
Tipo de recurso:
Artículo publicado
Clasificación temática:
Resumen
Substantial efforts have been made to understand the immune response during severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, in order to identify and characterize risk factors, immune mechanisms responsible for the induction of tissue injury and potential therapeutic targets. Purinergic signaling pathway has shown to modulate the inflammatory processes in the course of several infectious diseases, but its role in the coronavirus disease 2019 (COVID-19) has not been clearly defined. Inflammation is usually associated to the release of ATP from different cell types, starting a cascade of events through the activation of a set of different purinergic receptors. This review summarizes the evidence showing the involvement of the purinergic system in the inflammatory condition that characterizes severe COVID-19.
Palabras clave:
SARS-CoV-2
,
Purinergic signaling
,
Inflammation
,
severe COVID-19
Archivos asociados
Licencia
Identificadores
Colecciones
Articulos(INBIRS)
Articulos de INSTITUTO DE INVESTIGACIONES BIOMEDICAS EN RETROVIRUS Y SIDA
Articulos de INSTITUTO DE INVESTIGACIONES BIOMEDICAS EN RETROVIRUS Y SIDA
Citación
Arruvito, Maria Lourdes; Sananez, Inés; Seery, Vanesa; Russo, Constanza; Geffner, Jorge Raúl; Purinergic signaling pathway in severe COVID-19; Elsevier; Current Opinion In Pharmacology; 70; 102379; 6-2023; 1-19
Compartir
Altmétricas